Literature DB >> 1087955

Treatment of Pneumocystis carinii pneumonia: current status of the regimens of pentamidine isethionate and pyrimethamine-sulfadiazine.

R C Young, V T DeVita.   

Abstract

A randomized clinical trial is under way comparing the relative merits of pentamidine isethionate and pyrimethamine-sulfadiazine in the management of patients with Pneumocystis carinii pneumonia. Twenty-one patients have entered the trial. Both regimens have produced at least one complete recovery in biopsy-proved pneumocystis pneumonia. Two patients have died from pneumocystis pneumonia after being treated with a combination of both regimens. Initial observations on comparative toxicity indicate pentamidine isethionate has more local toxicity, but pyrimethamine-sulfadiazine is difficult to administer to severely ill patients. Comparative merits of the two regimens will be analyzed at the completion of the present clinical trial.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1087955

Source DB:  PubMed          Journal:  Natl Cancer Inst Monogr        ISSN: 0083-1921


  4 in total

Review 1.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

2.  Pneumocystis carinii pneumonia: a light microscopical and ultrastructural study.

Authors:  P S Hasleton; A Curry; E M Rankin
Journal:  J Clin Pathol       Date:  1981-10       Impact factor: 3.411

3.  Alveolar response to experimental Pneumocystis carinii pneumonia in the rat.

Authors:  P N Lanken; M Minda; G G Pietra; A P Fishman
Journal:  Am J Pathol       Date:  1980-06       Impact factor: 4.307

4.  Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J M Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.